D-Street expects moderate index returns in 2020, financial stocks most preferred
Maybank Kim Eng is ‘neutral’ on the Indian stock market in 2020.

BNP Paribas
The firm has an overweight stance on Sensex and expects it to reach 44,500 in 2020. BNP expects further cuts in India’s GDP growth estimates as the consensus estimates do not seem to reflect the recent deceleration fully. The room for the government to do fiscal stimulus through increased spending or further tax cuts seems limited due to stretched fiscal position, said BNP Paribas. Private investments are unlikely to pick up anytime soon and asset quality pressure on financials does not appear to be behind yet, said BNP. The brokerage is overweight on India despite macro-economic headwinds because Indian equities are one of the rare compounders in Asian markets. Ease of stock selection and availability of diverse range of sectors to invest remain bright spots, said BNP.
Investment picks: Private banks, insurance, frontline IT companies and investing in undervalued rebounders.
Maybank Kim Eng Securities
Investment picks: ICICI Bank, Axis Bank, Bharti Airtel, Power Grid, UltraTech, Mahanagar Gas, Dalmia Bharat, Mahindra, HCL Tech, Mphasis and Tech Mahindra. Maruti Suzuki and Tata Motors are top sell recommendations.
ICICI Securities
The brokerage has a Nifty target of 13,100 by December 2020. Absolute returns for the Nifty in 2020 will be constrained by the sharp run-up in stocks during the fourth quarter of calendar year 2019 which has stretched valuations, said ICICI. Skepticism towards risk assets could continue in 2020 as global central banks’ appetite for gold continues especially in an environment of negative rates in developed economies, said ICICI Securities. The brokerage has an overweight stance on financials, consumer discretionary and industrials.
Credit Suisse
Investment picks: SBI, ICICI Bank, ICICI Prudential Life among financials, Bharti Airtel in telecom, Power Grid among utilities and Tata Steel among metals. The brokerage has a minor overweight on pharma and IT.
Download ET Markets APP